Drug Trial Radar · NCT01313650
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,538
Actual
Start
Mar 1, 2011
Primary completion
Apr 1, 2012
Study completion Apr 5, 2012
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
62.5/25mcgDrug
GSK573719/GW64244
62.5mcgDrug
GSK573719
25mcgDrug
GW642444
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)Time frame: Baseline and Day 169
Locations
165 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Ormond Beach, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Lawrenceville, Georgia
GSK Investigational Site
Coeur d'Alene, Idaho
GSK Investigational Site
Lafayette, Indiana
GSK Investigational Site
Olathe, Kansas
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Madisonville, Kentucky
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Sunset, Louisiana
GSK Investigational Site
Cadillac, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Omaha, Nebraska
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Larchmont, New York
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Dayton, Ohio
GSK Investigational Site
Medford, Oregon
GSK Investigational Site
Beaver, Pennsylvania
GSK Investigational Site
Erie, Pennsylvania
GSK Investigational Site
Phoenixville, Pennsylvania
GSK Investigational Site
Gaffney, South Carolina
GSK Investigational Site
Greenville, South Carolina
GSK Investigational Site
Pelzer, South Carolina
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Rapid City, South Dakota
GSK Investigational Site
Johnson City, Tennessee
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Kingwood, Texas
GSK Investigational Site
Abingdon, Virginia
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Richmond, Virginia
GSK Investigational Site
Dimitrovgrad, Bulgaria
GSK Investigational Site
Pleven, Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.